FDA 2004 Reg Agenda Includes CFC Albuterol Phase Out, Final Label Rule
Executive Summary
FDA will begin the phase out of CFC-containing albuterol products during 2004, according to HHS' semiannual regulatory agenda published in the Dec. 22 Federal Register
You may also be interested in...
FDA Regulatory Agenda Includes “Complete Response” Rule, E-Drug Listing
A notice of proposed rulemaking for FDA's "complete response" regulation is scheduled for publication in July, according to HHS' semiannual regulatory agenda published in the June 28 Federal Register
FDA Regulatory Agenda Includes “Complete Response” Rule, E-Drug Listing
A notice of proposed rulemaking for FDA's "complete response" regulation is scheduled for publication in July, according to HHS' semiannual regulatory agenda published in the June 28 Federal Register
Aventis Divests Azmacort For $200 Mil.; Kos To Back Relaunch With 500 Reps
Kos Pharmaceuticals will relaunch Azmacort with a 490-representative sales force following its $200 mil. purchase of the inhaled corticosteroid from Aventis